OG-CIRIUM
Over 180 of the major global airlines were on time in 2020, according to a new report by Cirium, the global aviation data company. The Cirium Airline Insights Review 2020 reveals that only 30 major airlines achieved this standard pre-pandemic. But over 60%—or 180 of 300 airlines globally—achieved a 90% or higher on-time arrival percentage since February 2020.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210104005632/en/
On-time performance of the top 300 global airlines significantly improved as COVID-19 reduced the number of flights in the air. In 2020, airlines only flew half of the flights flown the previous year.
“The pandemic caused a significant reduction in flight volume with airlines operating 49% fewer flights in 2020. The factors that normally cause flight delays didn’t exist, such as congestion at the airport. Overall global passenger traffic was down in 2020 by 67% from the previous year,” said Jeremy Bowen, CEO of Cirium.
Cirium’s top 10 league table for flights operated by country shows that the majority of flights were operated in the US, despite a 42% year-over-year drop in the market. China maintained its position, with only 24% of that market’s flights down versus 2019.
Japan overtook India, moving up to 3rd place as India’s flights were down 50% versus 2019. The UK was hit heavily with 67% of flights down compared to last year, moving it to 8th place from 5th . Russia moved from 10th place in 2019 to 5th in 2020 and Indonesia moved into the top 10.
Top 10 countries by passenger flights flown 2020 |
||||
Rank |
Country |
Total flights flown 2020 |
Rank in 2019 |
% YoY diff |
1 |
United States |
5.1M |
#1 |
-42% |
2 |
China |
3.4M |
#2 |
-24% |
3 |
Japan |
638K |
#4 |
-43% |
4 |
India |
592K |
#3 |
-50% |
5 |
Russia |
486K |
#10 |
-34% |
6 |
Brazil |
382K |
#9 |
-53% |
7 |
Spain |
352K |
#7 |
-61% |
8 |
United Kingdom |
340K |
#5 |
-67% |
9 |
Indonesia |
333K |
#12 |
-53% |
10 |
Mexico |
332K |
#15 |
-44% |
Source: Cirium Core, flights tracked data (passenger flights - narrowbody, widebody and regional) for Jan 1 to Dec 31, date filed Jan 1, 2021 |
||||
Asia-Pacific carriers recovered much quicker in 2020 than their global peers and rose in the rankings in flights operated. Out of the top 10 global airlines, China Southern Airlines’ passenger flights only dropped 28% versus 2019. United Airlines was the most impacted of the top 10, with a 54% drop in flights flown versus 2019.
No European carriers feature in the 2020 list. Ryanair moved to 13th place (from 6th ) as the airline’s flights flown were down 72% versus the year before. Lufthansa was 11th in 2019 but missed out on the 2020 top 10, finishing at 29th place as flights flown dropped by 69% in 2020.
Top 10 airlines by passenger flights flown 2020 |
|||||
Rank |
Airline code |
Airline |
Total flights flown 2020 |
Rank in 2019 |
% YoY diff |
1 |
WN |
Southwest Airlines |
896K |
#1 |
-34% |
2 |
AA |
American Airlines |
622K |
#3 |
-44% |
3 |
DL |
Delta Air Lines |
619K |
#2 |
-46% |
4 |
OO |
SkyWest Airlines |
597K |
#4 |
-30% |
5 |
CZ |
China Southern Airlines |
521K |
#7 |
-28% |
6 |
UA |
United Airlines |
372K |
#5 |
-54% |
7 |
MU |
China Eastern Airlines |
321K |
#9 |
-33% |
8 |
CA |
Air China |
312K |
#10 |
-30% |
9 |
6E |
IndiGo |
281K |
#8 |
-45% |
10 |
YX |
Republic Airways |
217K |
#15 |
-37% |
Source: Cirium Core, flights tracked data (passenger flights - narrowbody, widebody and regional) for Jan 1 to Dec 31, date filed Jan 1, 2021 |
|||||
“Domestic travel has recovered faster and airlines with a dominant domestic market come back quicker,” Bowen said. “That is especially the case in Asia-Pacific where recovery is more positive. The US and Europe have experienced setbacks with government-enforced restrictions and additional waves of COVID-19 affecting travel.”
Travel restrictions and the shift to more leisure travel versus business travel changed the top 10 league table for flights flown by airport extensively.
Chicago O’Hare is usually the busiest airport globally for passenger flights, however the pandemic caused a 46% reduction in flights for the airport in 2020. Three Chinese airports—Guangzhou Baiyun, Chengdu Shuangliu, and Shenzhen Bao’an—moved into the global top 10 busiest airports by arriving passenger flights.
Top 10 airports by passenger flights flown 2020 |
|||||
Rank |
Airport code |
Airport |
Total flights flown 2020 |
Rank in 2019 |
% YoY diff |
1 |
ATL |
Atlanta US |
260K |
#2 |
-40% |
2 |
DFW |
Dallas US |
235K |
#3 |
-30% |
3 |
ORD |
Chicago US |
234K |
#1 |
-46% |
4 |
DEN |
Denver US |
202K |
#5 |
-32% |
5 |
CLT |
Charlotte US |
182K |
#7 |
-32% |
6 |
CAN |
Guangzhou CN |
165K |
#13 |
-28% |
7 |
LAX |
Los Angeles US |
156K |
#4 |
-50% |
8 |
CTU |
Chengdu CN |
148K |
#37 |
-16% |
9 |
SZX |
Shenzhen CN |
139K |
#42 |
-16% |
10 |
SEA |
Seattle US |
137K |
#18 |
-36% |
Source: Cirium Core, flights tracked data (passenger flights - narrowbody, widebody and regional) for Jan 1 to Dec 31, date filed Jan 1, 2021 |
|||||
In 2019, London Heathrow was the 9th busiest airport for flights flown. In 2020, it ranked 31st and flights operating there were down 61% versus 2019. Amsterdam Airport Schiphol was the busiest airport in Europe. Flight operations there dropped 57% in 2020 and as a result the airport sits at 27th globally.
The Cirium Airline Insights Review 2020 provides additional insights on 2020 air travel industry and includes The On-Time Performance Review 2020 by Cirium.
To read the full Cirium Airline Insights Review 2020 – click here .
Ends
Note to editors:
Data for the passenger flights flown is based on set criteria, which includes passenger flights only (including combination flights – passenger and cargo) that are scheduled and aircraft market classes of narrowbody, widebody, and regional jets. It excludes other types, such as cargo and business jet flights, as well as unscheduled flights.
For further information please visit www.cirium.com and follow Cirium updates via LinkedIn and Twitter .
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210104005632/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
